Simcere Pharmaceutical Group Limited (HKG:2096)

Market Cap	32.08B
Revenue (ttm)	7.79B
Net Income (ttm)	964.48M
Shares Out	2.60B
EPS (ttm)	0.39
PE Ratio	31.51
Forward PE	22.67
Dividend	0.17 (1.48%)
Ex-Dividend Date	Jun 18, 2025

Volume	15,432,000
Average Volume	8,670,258
Open	11.99
Previous Close	11.85
Day's Range	11.75 - 12.59
52-Week Range	6.15 - 15.08
Beta	0.52
RSI	45.71
Earnings Date	Nov 14, 2025

About HKG:2096

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 6,584
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2096

Financial Performance

In 2024, HKG:2096's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY